Stephens & Co. Initiates Coverage On Palvella Therapeutics with Overweight Rating, Announces Price Target of $220

Palvella

Palvella

PVLA

0.00

Stephens & Co. analyst Sudan Loganathan initiates coverage on Palvella Therapeutics (NASDAQ: PVLA) with a Overweight rating and announces Price Target of $220.